Work

Editorial: Challenges and opportunities of TKIs in the treatment of NSCLC patients with uncommon mutations

Year: 2022

Type: editorial

Abstract: Editorial on the Research TopicChallenges and Opportunities of TKIs in the Treatment of NSCLC patients with Uncommon Mutations Substantial advances have been made in our understanding of the molecular biology of cancer, leading to profound progression in the fields of diagnosis and treatment of non-small cell lung cancer (NSCLC).More recently, many uncommon mutations are gaining attention in NSCLC, including epidermal growth factor receptor exon 20 insertion (EGFR 20ins), anaplastic lymphoma kinase (ALK), human epidermal growth factor receptor 2 (HER2), rearranged during transfection (RET), v-Raf murine sarcoma viral oncogene homolog B (BRAF), neurotrophic tropomyosin receptor kinase (NTRK), and others (1).Pharmaceutical agents developed to target classical driver mutations detected in NSCLC patients have provided profound and durable responses compared with conventional chemotherapy.This paradigm shift can also be seen in the realm of uncommon mutations.Ongoing studies and clinical trials of tyrosine kinase inhibitors (TKIs) for uncommon targets are gaining insights into possible treatment options to enable long-term survival of patients.Since immunotherapy serves as the backbone treatment in mutation-negative populations, the efficacy of immunotherapy or immunotherapy-based combinations has also been evaluated in patients harboring uncommon targets.Furthermore, other novel therapies and platforms have been developed and tested to provide more possibilities and options for these patients.In this special issue, we compiled a series of papers including original research, reviews and case reports that focus on recent advances and challenges in the treatment of lung cancer patients with uncommon driver mutations.For rare EGFR mutations, Xu et al. reported that two patient-derived xenografts in zebrafish embryos from two patients Frontiers in Oncology frontiersin.

Source: Frontiers in Oncology

DOI: 10.3389/fonc.2022.970315

Authors: Chunxia Su, Shi-Yong Sun

Institutions: Tongji University, Shanghai Pulmonary Hospital, Emory University, Winship Cancer Institute

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,950